Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of <i>TP53</i>: Final Results of the National Cancer Research Institute CLL206 Trial - Concepedia

Concepedia

Publication | Closed Access

Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of <i>TP53</i>: Final Results of the National Cancer Research Institute CLL206 Trial

164

Citations

40

References

2012

Year

Andrew R. Pettitt, Richard E. Jackson, Stacey Carruthers, James Dodd, Susanna Dodd, Melanie Oates, Gillian G. Johnson, Anna Schuh, Estella Matutes, Claire Dearden,

Journal of Clinical Oncology

Abstract

Alemtuzumab plus methypredisolone is the most effective induction regimen hitherto reported in TP53-deleted CLL. The risk of infection is age related and, in younger patients, seems only marginally higher than that associated with rituximab, fludarabine, and cyclophosphamide.

References

	Year	Citations

Page 1